Skip to main content
. 2021 Apr 16;24:905–922. doi: 10.1016/j.omtn.2021.04.011

Figure 1.

Figure 1

MIR210HG may be the core molecule that induces endometrial cancer

(A) The volcano plot obtained using data from TCGA database. The red points represent upregulated genes screened based on fold change >1.9 and a corrected p value of <0.05. (B) mRNA expression of RP6-65G23.3, MIR210HG, SNHG25, HAGLROS, BMPR1B-AS1, RP1-86C11.7, and LINC00261 in TCGA cohort of endometrial tissues, tumor n = 548, compared with normal endometrial tissue (n = 35), (the controls were collected from paracancerous tissues in patients with endometrial cancer). (C) The heatmap shows that lncRNA overexpression was the most in GSE17025 cohorts. (D) Expression of MIR210HG in 40 endometrial cancer tissues and 20 normal tissues determined using quantitative real-time PCR. (E) Relative expression of MIR210HG in endometrial cancer tissues analyzed according to the tumor stage and lymph node metastasis. (F) Expression of MIR210HG in 78 endometrial cancer tissues and 19 normal tissues analyzed using in situ hybridization assay. (G) Disease-free survival curves for endometrial carcinoma patients (n = 78) indicate that high expression of MIR210HG correlates with poor clinical outcomes. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.